|Expense Ratio (net)||1.00%|
|Last Cap Gain||0.00|
|Morningstar Risk Rating||Below Average|
|5y Average Return||N/A|
|Average for Category||N/A|
|Inception Date||Jul 15, 1970|
Jan.09 -- Melanie Perkins, Cava's co-founder and chief executive officer, discusses the startup's strategy with Bloomberg's Haidi Lun and Betty Liu on "Bloomberg Daybreak: Australia."
NEW YORK, Nov. 7, 2017 /PRNewswire/ -- Milberg LLP, an investor and consumer protection firm, is investigating whether the Sequoia Fund (SEQUX) damaged its shareholders in violation of law by breaching obligations to them with respect to the size of its investments in Valeant Pharmaceuticals International Inc. ("Valeant"). Pursuant to Sequoia Fund's concentration policy, which is stated in its offering prospectus, Sequoia Fund was not allowed to invest more than 25% of Sequoia's assets in one industry. In 2010, however, Sequoia Fund invested in Valeant to the tune of 9.2% of the fund's assets. In 2015, Valeant was engulfed in a scandal stemming from its practice of acquiring drugs and raising prices dramatically, drawing significant political and public scorn. Accusations soon followed by investigative journalists, investments analysts, and short sellers, of questionable accounting and business practices, which caused Valeant's stock price to plummet.